IBA Overhauls Leadership Team to Accelerate Growth Strategy
Event summary
- Olivier Legrain steps down as CEO, becomes Vice-Chairman of the Board, effective June 17, 2026.
- Henri de Romrée, Deputy CEO, takes over strategic and operational responsibilities for all Group activities.
- Catherine Vandenborre appointed Chief Ventures & Corporate Officer, overseeing partnerships, innovation, and finance.
- Transition follows three years of preparation, with de Romrée joining in November 2023 and Vandenborre in July 2025.
- IBA's revenue grew from €225M to €620M under Legrain's leadership since 2012.
The big picture
IBA's leadership transition reflects a deliberate effort to institutionalize its growth strategy amid increasing competition in advanced radiation therapy and nuclear medicine. The shift comes as the company seeks to balance operational scaling with long-term innovation, particularly in emerging healthcare technologies. With revenue surpassing €600M, the governance realignment aims to ensure continuity while enabling agile decision-making in a rapidly evolving sector.
What we're watching
- Execution Risk
- Whether Henri de Romrée can sustain IBA's growth momentum while navigating operational complexities.
- Strategic Focus
- How Catherine Vandenborre's dual role in ventures and corporate functions will impact innovation and financial discipline.
- Market Leadership
- The pace at which IBA can strengthen its position in proton therapy and expand into nuclear medicine and industrial solutions.
Related topics